Mitochondrial ROS-Targeting Compositions for Post-CPR Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for post-cardiopulmonary resuscitation (CPR) injury, particularly cardiogenic shock and myocardial stunning, are lacking, and the molecular mechanisms mediating these conditions are not well understood, leading to high morbidity and mortality.
Innovation Solution
Administering a pharmaceutical composition that includes a compound, such as S1QEL, to inhibit H2O2 production at specific sites of mitochondrial electron transport complexes (IQ, IIF, or IIIQ0) to reduce ROS generation and improve mitochondrial function, myocardial contractility, and neurological outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If mitochondrial electron transport is inhibited to reduce H2O2 production, then ROS generation is reduced, but metabolism is negatively affected
Solution Approach 1:
The patent applies local quality by using site-specific inhibitors that target only particular locations within the mitochondrial electron transport chain (Complex I site IQ, Complex II site IIF, or Complex III site IIIQ0) rather than broadly inhibiting the entire chain. This localized approach allows selective reduction of H2O2 production at specific problematic sites while preserving overall mitochondrial function and metabolism.
Solution Approach 2:
The patent employs small molecule compounds as intermediaries that bind to specific sites on electron transport complexes to modulate their activity. These intermediary compounds act as selective modulators that can reduce electron leak and H2O2 production without completely blocking electron flow, thereby maintaining metabolic function while reducing ROS generation.
2Reliability
If conventional therapies are used for post-CPR injury, then treatment is provided, but effectiveness is limited due to lack of understanding of molecular mechanisms
Solution Approach 1:
The patent applies preliminary action by administering site-specific electron leak inhibitors during or immediately after CPR to prevent the development of myocardial stunning and cardiogenic shock before they fully manifest. This early intervention targets the underlying molecular mechanisms (electron leak and H2O2 production) before they cause irreversible damage, improving treatment effectiveness.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific supportive care to targeted molecular intervention by using compounds that specifically modify electron transport parameters (reducing electron leak and H2O2 production at specific sites). This parameter change addresses the root molecular mechanisms rather than just treating symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces post-CPR cardiac mitochondrial ROS generation, improves myocardial contractility and neurological function, increases the rate of return to spontaneous circulation, and enhances survival rates in subjects.
Implementation Method 1
a compound that reduces or inhibits H2O2 production induced by electron leak at sites IQ (the ubiquinone-binding site of Complex I, the active site during reverse electron transport), IIF (the flavin site of Complex II), or IIIQ0 (the outer ubiquinone-binding site of Complex III)
Implementation Method 2
Mitochondria are dynamic organelles undergoing regulated fusion (joining) and fission (dividing) events (12, 13). This group was the first to demonstrate evidence of mitochondrial fission following CA, its mediation of myocardial dysfunction through fission-induced ROS generation (14).
Data Source
AI summary
This disclosure relates generally to compositions and methods for treating and preventing post-cardiopulmonary resuscitation injury.